Clinical trials: Neoplasms, Metastatic
Bladder Cancer
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after…
- Trial name
- NCT02756637
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer Metastatic
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy.
- Trial name
- EPOCH (NCT01483027)
- Testing
- TheraSphere
- Where
- 131 sites in United States, Austria and 11 more
- Volunteers
- 428 people
- Sponsor
- Boston Scientific Corporation
Breast Cancer
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
RATIONALE: Giving chemotherapy before a donor natural killer (NK) cell infusion helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's cells.
- Trial name
- NCT00376805
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastric Cancer Adenocarcinoma Metastatic
Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.
- Trial name
- NCT00517829
- Testing
- Docetaxel, cetuximab, oxaliplatin
- Where
- 47 sites in United States
- Volunteers
- 150 people
- Sponsor
- US Oncology Research
Gastric Cancer
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy of ipatasertib in combination with oxaliplatin, 5-fluorouracil, and leucovorin (modified FOLFOX6 [mFOLFOX6]) chemotherapy in…
- Trial name
- NCT01896531
- Testing
- 5-Fluorouracil, Ipatasertib, Leucovorin
- Where
- 34 sites in United States, France and 9 more
- Volunteers
- 153 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired…
- Trial name
- NCT02083653
- Testing
- Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC)
- Where
- 54 sites in United States, Austria and 8 more
- Volunteers
- 254 people
- Sponsor
- Symphogen A/S
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Invasive Breast Cancer, Metastatic Breast Cancer
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
- Conditions
- Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT04448886
- Testing
- Pembrolizumab, Sacituzumab Govitecan
- Where
- 8 sites in United States
- Volunteers
- 110 people
- Sponsor
- Ana C Garrido-Castro, MD
Neoplasms, Neoplasm Metastasis
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for…
- Conditions
- Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT03166631
- Testing
- BI 891065, BI 754091
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Metastatic Carcinoma
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
This is an open label single arm phase 2 clinical trial in patients with metastatic solid malignancy of any histology who have previously experienced limited progression in at least 1 and up to 5 lesions while on immune…
- Trial name
- NCT04376502
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baptist Health South Florida
Non Small Cell Lung Cancer
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- HBI-8000 (NCT05141357)
- Testing
- HBI-8000 in combination with pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- HUYABIO International, LLC.
Colon Cancer
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
This is an exploratory biomarker study. Patients with metastatic colorectal cancer will receive regorafenib, which is FDA approved in this setting, on day 1-21 of every consecutive 28 day cycle.
- Trial name
- NCT02402036
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University
Metastatic Colorectal Cancer, Metastatic Breast Cancer
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer
This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer.
- Trial name
- BRECOL (NCT01733628)
- Where
- 10 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Spanish Breast Cancer Research Group
Pancreatic Adenocarcinoma, Metastatic
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
- Trial name
- VIRAGE (NCT05673811)
- Testing
- Nab-paclitaxel, Gemcitabine, VCN-01
- Where
- 17 sites in United States, Spain
- Volunteers
- 112 people
- Sponsor
- Theriva Biologics SL
Head and Neck Cancer
Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
- Trial name
- NCT03938337
- Testing
- Cohort 1 Not Previously Treated, Cohort 2 Treated Previously
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of GDC-0810 compared with fulvestrant in postmenopausal women with advanced or metastatic estrogen receptor positive (ER+)/ human epidermal…
- Trial name
- HydranGea (NCT02569801)
- Testing
- Fulvestrant, GDC-0810
- Where
- 44 sites in United States, Australia and 4 more
- Volunteers
- 71 people
- Sponsor
- Genentech, Inc.
Melanoma, Skin Neoplasms
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate.
- Trial name
- NCT00094107
- Testing
- Axitinib [AG-013736]
- Where
- 12 sites in United States, France
- Volunteers
- 32 people
- Sponsor
- Pfizer
Breast Cancer
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or…
- Trial name
- NCT01234337
- Testing
- Sorafenib (Nexavar, BAY43-9006), Capecitabine
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 537 people
- Sponsor
- Bayer
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT03325101
- Testing
- Cryosurgery, Pembrolizumab, Pheresis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.